J&J Shines Spotlight On U.S. OTC Sales Growth
This article was originally published in The Tan Sheet
Executive Summary
Domestic OTC sales grow nearly 20% to $644 million as J&J remains on track to return 75% of recalled McNeil products to market. Consumer business head Sandra Peterson says the firm began breaking out OTC sales figures to single out how the business is doing.
You may also be interested in...
J&J OTC Business Returns To Double-Digit U.S. Growth In Q1
The domestic OTC/nutritionals business grew more than 14% in the first quarter on the strength of McNeil products returning to market and a severe cold and flu season. Johnson & Johnson’s consumer performance exceeded some market analyst estimates.
J&J Prioritizes OTC Return With McNeil Remediation End In Sight
Johnson & Johnson CEO Alex Gorsky says bringing recalled OTCs such as Tylenol and Motrin products back to market is the firm’s “clear number one priority” in the near term. J&J also has a timetable for completing its responsibilities under a consent decree with FDA in place since 2011.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.